Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Primary listing
Employees
437
Headquarters
Website
CRNX Metrics
BasicAdvanced
$4.3B
-
-$4.12
0.33
-
Price and volume
Market cap
$4.3B
Beta
0.33
52-week high
$59.95
52-week low
$24.10
Average daily volume
1.9M
Financial strength
Current ratio
17.797
Quick ratio
17.492
Long term debt to equity
3.698
Total debt to equity
4.262
Profitability
EBITDA (TTM)
-419.617
Gross margin (TTM)
-10,919.32%
Net profit margin (TTM)
-26,568.53%
Operating margin (TTM)
-30,392.17%
Management effectiveness
Return on assets (TTM)
-23.77%
Return on equity (TTM)
-36.94%
Valuation
Price to revenue (TTM)
2,947.694
Price to book
3.68
Price to tangible book (TTM)
3.68
Price to free cash flow (TTM)
-13.418
Free cash flow yield (TTM)
-7.45%
Free cash flow per share (TTM)
-3.41
Growth
Revenue change (TTM)
0.51%
Earnings per share change (TTM)
9.88%
3-year revenue growth (CAGR)
-33.10%
3-year earnings per share growth (CAGR)
11.82%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
Bulls say / Bears say
Palsonify's FDA approval establishes it as the first once-daily oral treatment for acromegaly, a key milestone that broadens care options for patients (Reuters).
The once-daily oral dosing of Palsonify offers patients a more convenient alternative to monthly injections, which could boost adherence and satisfaction (Reuters).
Analysts predict that Palsonify could achieve peak annual sales of $1.5 billion by 2030, pointing to strong revenue prospects (Reuters).
Palsonify will face competition from Chiesi’s Mycapssa and injectable somatostatin analogs made by Pfizer and Novartis, which may limit both its market share and pricing power (Reuters).
Crinetics must still engage with stakeholders and negotiate with payers before its planned early October launch; these hurdles could slow down initial commercial adoption (Reuters).
As a clinical-stage company without product revenues, Crinetics is highly dependent on Palsonify’s commercial launch for profitability, adding significant execution risk (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $4.3B as of October 11, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of October 11, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.